MAY – JUNE 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA May 28 – Selpercatinib – Solid Tumours RET. The European Commission (EC) has approved the extension of indication for the RET receptor tyrosine kinase inhibitor to include the treatment, in monotherapy, of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no […]